Autoimmune hepatitis and IgG4-related disease.


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
21 May 2019
Historique:
received: 08 03 2019
revised: 13 04 2019
accepted: 19 04 2019
entrez: 1 6 2019
pubmed: 1 6 2019
medline: 4 12 2019
Statut: ppublish

Résumé

IgG4-related disease (IgG4-RD) is a chronic-fibroinflammatory disorder affecting a wide range of organs. Elevation of serum IgG4 concentrations and abundant infiltration of IgG4-expressing plasma cells are key diagnostic features of this autoimmune disease. Although common organ involvement of IgG4-RD includes the salivary glands, pancreas, and bile duct, hepatic involvement is less well established. Recently, five studies identified a subtype of autoimmune hepatitis (AIH), called IgG4-associated AIH (IgG4-AIH). IgG4-AIH is diagnosed based on significant accumulation of IgG4-expressing plasmacytes in the liver in patients who met the diagnostic criteria for classical AIH. Although four of the five reports regarded IgG4-AIH based on hepatic accumulation of IgG4-positive cells alone, one report diagnosed IgG4-AIH based on both hepatic accumulation of IgG4-positive cells and elevated serum concentrations of IgG4. IgG4-AIH diagnosed based on the latter criteria may be a hepatic manifestation of IgG4-RD whereas IgG4-AIH diagnosed based on the former criteria may be a subtype of AIH. In this review article, we summarize and discuss clinicopathological features of IgG4-AIH.

Identifiants

pubmed: 31148902
doi: 10.3748/wjg.v25.i19.2308
pmc: PMC6529891
doi:

Substances chimiques

Immunoglobulin G 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2308-2314

Commentaires et corrections

Type : CommentIn

Déclaration de conflit d'intérêts

Conflict–of-interest statement: No potential conflicts of interest. No financial support.

Références

J Hepatol. 1999 Nov;31(5):929-38
pubmed: 10580593
N Engl J Med. 2006 Jan 5;354(1):54-66
pubmed: 16394302
Gut. 2007 Oct;56(10):1471-2
pubmed: 17504944
Mod Pathol. 2007 Aug;20(8):884-94
pubmed: 17571078
Hepatology. 2007 Aug;46(2):463-71
pubmed: 17634963
Liver Int. 2010 Feb;30(2):222-31
pubmed: 19650840
Gastroenterology. 2010 Jul;139(1):58-72.e4
pubmed: 20451521
J Gastroenterol. 2011 Jan;46 Suppl 1:48-55
pubmed: 20862498
N Engl J Med. 2012 Feb 9;366(6):539-51
pubmed: 22316447
Gut. 2013 Sep;62(9):1373-80
pubmed: 23749606
Lancet. 2013 Oct 26;382(9902):1433-44
pubmed: 23768844
World J Gastroenterol. 2013 Nov 21;19(43):7661-70
pubmed: 24282356
Autoimmun Rev. 2014 Dec;13(12):1203-10
pubmed: 25151972
Aliment Pharmacol Ther. 2014 Dec;40(11-12):1251-61
pubmed: 25312536
J Immunol. 2015 Oct 1;195(7):3033-44
pubmed: 26297761
Dig Liver Dis. 2016 Mar;48(3):302-8
pubmed: 26553036
Trop Gastroenterol. 2015 Apr-Jun;36(2):112-7
pubmed: 26710480
Semin Liver Dis. 2016 Aug;36(3):229-41
pubmed: 27466793
Curr Top Microbiol Immunol. 2017;401:19-33
pubmed: 28197739
Pathol Res Pract. 2017 May;213(5):565-569
pubmed: 28238541
J Immunol. 2017 May 15;198(10):3886-3896
pubmed: 28373582
Gut. 2018 Apr;67(4):728-735
pubmed: 28765476
J Allergy Clin Immunol. 2019 Feb;143(2):736-745.e6
pubmed: 29852256
Sci Transl Med. 2018 Aug 8;10(453):null
pubmed: 30089633
J Gastroenterol Hepatol. 2019 Apr;34(4):742-746
pubmed: 30378176
Trends Immunol. 2018 Nov;39(11):874-889
pubmed: 30401468

Auteurs

Kosuke Minaga (K)

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.

Tomohiro Watanabe (T)

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan. tomohiro@med.kindai.ac.jp.

Hobyung Chung (H)

Department of Gastroenterology and Hepatology, Kobe City General Hospital, Chuo-ku, Kobe 650-0047, Japan.

Masatoshi Kudo (M)

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH